Molecular signature of cutaneous pigmentary spots, associated with the extracellular matrix

A method for evaluating the efficacy of a treatment for cutaneous pigmentary spots, comprising comparing the levels of expression in a skin sample obtained from said spot, before and after treatment, of at least one dermal gene linked to the extracellular matrix selected from the list constituted by the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7 and SOSTDC1, or indeed from the list constituted by the genes FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV, ITGB1 and ACTN1.

An in vitro method for evaluating the efficacy of a treatment of cutaneous pigmentary spots, comprising comparing, before and after treatment, the level of expression, in a cellular model representing the skin, of at least one dermal gene linked to the extracellular matrix selected from the list constituted by the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7 and SOSTDC1, or indeed from the list constituted by the genes FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV, ITGB1 and ACTN1, or indeed the level of expression or activity of an expression product of said selected gene.

A cosmetic method for the treatment or prevention of a non-pathological cutaneous pigmentary spot of human skin, comprising modulating the level of expression or activity of a dermal gene linked to the extracellular matrix, where said gene is selected from the list constituted by the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7 and SOSTDC1 or indeed from the list constituted by the genes FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV and ACTN1.

Use of a modulator of the level of expression or activity of an expression product of at least one dermal gene selected from the list constituted by the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7 and SOSTDC1, or from the list constituted by the genes FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV and ACTN1, for a cosmetic application in the treatment of non-pathological cutaneous pigmentary spots, said modulator modifying the level of expression or activity of the expression product of the selected gene or genes.

A modulator of the level of expression or activity of the expression product of at least one dermal gene selected from the list constituted by the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7 and SOSTDC1, or from the list constituted by the genes FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMBS, LAMA3, ITGAV and ACTN1, for an application in the treatment of cutaneous pigmentary spots, said modulator modifying the level of expression or activity of the expression product of the selected gene or genes.